Wordt geladen...
Lenvatinib and radioiodine-refractory thyroid cancers
Over the past decade, several multikinase inhibitors have shown considerable effectiveness against metastatic radioiodine-refractory thyroid cancers in early stage clinical trials. On the basis of some remarkable results in a phase III clinical trial, lenvatinib now joins sorafenib as another multik...
Bewaard in:
| Gepubliceerd in: | Nat Rev Endocrinol |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4518863/ https://ncbi.nlm.nih.gov/pubmed/25824678 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrendo.2015.53 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|